1 / 48

Nicholas J. Okon,D.O. Medical Director St. Vincent Healthcare, Billings For the Montana Stroke Initiative

Nicholas J. Okon,D.O. Medical Director St. Vincent Healthcare, Billings For the Montana Stroke Initiative. http://montanastroke.org. Stroke Stats. 1 stroke very 53 seconds 1 death from stroke every 3.3 minutes (436/day) 750,000 new and recurrent strokes each year in US Mortality

adamdaniel
Download Presentation

Nicholas J. Okon,D.O. Medical Director St. Vincent Healthcare, Billings For the Montana Stroke Initiative

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nicholas J. Okon,D.O. Medical Director St. Vincent Healthcare, Billings For the Montana Stroke Initiative http://montanastroke.org

  2. Stroke Stats • 1 stroke very 53 seconds • 1 death from stroke every 3.3 minutes (436/day) • 750,000 new and recurrent strokes each year in US • Mortality • 7.6% 30d • 16-23% 3 months • Yellowstone County • 310 strokes expected

  3. Stroke is a treatable condition. • IV tPA is approved for use within 3 hours (NINDS) • Intra-arterial therapy has proven to be safe and effective within 6 hours (PROACT II) • Combined IV/IA may be more effective than IV t-PA (Interventional Management of Stroke -IMS) • Mechanical and laser catheter technologies are showing great promise (Angio-Jet)

  4. Stroke: The Challenge • Only 1-3% of all stroke victims receive treatment with tPA in the US • 25% of Acute MI patients receive treatment (lytics or PTCA) in the US • Mean time to presentation • AMI: 3hrs • Acute Stroke: 4-10hrs • 24-59% patients present within 3 hours • 40-76% patients present within 6 hours

  5. Reasons for lack of treatment: • Patient’s inability to recognize stroke symptoms • 40% of stroke patients can’t name a single sign or symptom of stroke or stroke risk factor. • 75% of stroke patients misinterpret their symptoms • 86% of patients believe that their symptoms aren’t serious enough to seek urgent care • Physician’s lack of experience with stroke treatment and therefore reluctance to “risk” treatment • Lack of organized delivery of care in many medical centers throughout the country.

  6. What is a stroke or TIA? • Stroke- • Sudden onset of focal neurologic deficits fitting a vascular distribution • TIA • Stroke-like symptoms lasting <1 hr and completely resolve • Most TIAs last 15-30 minutes

  7. Symptoms of stroke • Sudden numbness or weakness of the face, arm or leg, especially on one side of the body    • Sudden confusion, trouble speaking or understanding    • Sudden trouble seeing in one or both eyes    • Sudden trouble walking, dizziness, loss of balance or coordination    • Sudden, severe headache with no known cause

  8. Types of Stroke 85% Ischemic 15 % hemorrhagic

  9. Left MCA Syndrome • Language loss (aphasia) • Right hemiparesis • Right hemisensory loss • Right visual field cut • Left gaze preference

  10. Right MCA Syndrome • Left hemi-neglect • visual,spatial, • Left hemiparesis • Left hemisensory loss • Left visual field cut • Neglect of deficits • “anasgnosia”

  11. Stroke is due to sudden vascular occlusion ACA MCA

  12. Vascular occlusion causes stroke symptoms • 50-70% of all stroke is due to embolism (cardiogenic and artery-to-artery) • 80 % of acute strokes are due to MCA territory ischemia • Arterial occlusion is seen in 80-90% within 6-24° of symptom onset • Spontaneous recanalization seen in ~ 20% within 6 ° of symptoms

  13. Many Causes of Stroke

  14. Hypoglycemia Hyperglycemia Seizure Subdural Hematoma Stroke Mimics

  15. Hypoglycemia Hyperglycemia Seizure Subdural Stroke Mimics Altered consciousness Hemiparesis Glucose <50 or Glucose >300

  16. Hypoglycemia Hyperglycemia Seizure Subdural Stroke Mimics • Altered consciousness • Hemiparesis • (Todd’s paralysis) • History of seizures • Seizure medications

  17. Hypoglycemia Hyperglycemia Seizure Subdural Stroke Mimics Altered consciousness Hemiparesis Signs of trauma

  18. Field Assessment • “Load and GO !!!” • ABC’s • Vitals • Rhythm • Glucose • Bring witness/Meds

  19. Time dependent treatment • IV t-PA must be given within 3 hours from onset of symptoms or from “time last seen normal” • Intra-arterial (IA) therapy must be given within 3 hours 6 hours

  20. Establishing time of onset • Symptom onset or time last seen normal • Correlate times (alarms, work, drive time TV) • Corroborate time with witness • Bring witness to ER or at least obtain phone number where they can be reached

  21. Details of Facial Droop

  22. Details of Arm Drift

  23. Acute Management: Vitals A B C • Airway - secure? • Breathing - O2 Sat, CHF? • Circulation - BP too high or too low? A-Fib?

  24. Acute Management: History • Symptom onset or time last seen normal • Correlate times (alarms, work, drive time TV) • Corroborate with witness • Prodromal or previous symptoms/TIAs • Exclude stroke mimics (seizure,migraine hypoglycemia, orthostasis)

  25. Is the patient a thrombolytic candidate? • Onset < 6 hrs • CT negative for hemorrhage • Not anticoagulated (INR <1.5) NO YES  Keep BP < 220/120  ASA 325mg chewed  DVT prophylaxis -Heparin 5000 SQ BID •  Keep BP <185/110 •  < 3 hrs • -IV tPA •  3-6 hrs • -Intra-arterial t-PA

  26. Blood Pressure Management in Acute Ischemic Stroke No thrombolytics Thrombolytics BP >220/120 MAP>130 requires Labetalol 10-30 mg IV q 10-15min Enalapril 0.625-1.25 mg IV q 6-8hrs prn Nitroprusside 0.5-1.0 µg/kg/min cont. IV Nicardipine 2.5-15 mg/hr continuous IV DBP> 140 Nitroprusside 0.5-1.0 µg/kg/min cont. IV Nicardipine 2.5-15 mg/hr continuous IV BP > 185/110 Nitropaste 1-2 inches Labetalol 10-30 mg IV q 10-15min Enalapril 0.625-1.25 mg IV q 6-8hrs (watch for angioedema)

  27. Heparin ISNOT an acute treatment for stroke • There are no large randomized placebo controlled studies using IV heparin in acute ischemic stroke. • Prospective case series have had mixed results • Our best guide is from the International Stroke Trial (IST)

  28. International Stroke Trial (IST)Lancet 1997;349:1569-1581 19,435 (AIS < 48˚) Heparin (9717) No Heparin (9718) 12,500 IU*(4856) 5000 IU*(4860) ASA(2430) No ASA(2426) ASA(2432) No ASA(2429) ASA(4858) No ASA(4860) *Heparin 12,500 and 5000 Sub-Q BID; ASA 300 mg

  29. International Stroke Trial (IST)Lancet 1997;349:1569-1581

  30. International Stroke Trial (IST)Lancet 1997;349:1569-1581 • Net effect is zero • Increased rate of bleeding in the heparin group off-sets any benefit

  31. Aspirin IS a treatment for acute ischemic stroke • International Stroke Trial (IST) and Chinese Acute Stroke Trial (CAST) • ASA allocated patients (n= 40,000) had significantly fewer recurrent stroke at 14 days • ASA benefit was not off-set by an increase in hemorrhagic strokes • Significant reduction in death or any non-fatal stroke • ASA did contribute to significantly more transfused or fatal extracranial bleeds

  32. Aspirin IS a treatment for acute ischemic stroke Give ASA 160-325mg for acute stroke

  33. Stroke Therapy Pre t-PA

  34. Stroke Therapy: Thrombolytic Era

  35. “Time is Brain” • Treatment of stroke is a salvage procedure • Permanent deficits are dependent on: • Regional cerebral blood flow • Duration of ischemia • Experimental evidence demonstrates that significant volumes of neuronal tissue can be salvaged by reperfusion within the first 4 - 6 hours

  36. Thrombolytic Therapy for Acute Ischemic Stroke Onset of Symptoms Therapy < 3 hours IV t-PA 3-6 hours IA t-PA

  37. Fibrinolytic Therapy: Yes/No Checklist Inclusion Criteria (all “Yes” boxes must be checked before fibrinolytics are given) Yes  Age 18 years or older  Clinical diagnosis of ischemic stroke causing a measurable neurologic deficit  Time of symptom onset well established to be <180 minutes before treatment would begin

  38. Fibrinolytic Therapy: Yes/No Checklist Exclusion Criteria (all “No” boxes must be checked before fibrinolytics are given): No  Evidence of intracranial hemorrhage on noncontrast head CT  Only minor or rapidly improving stroke symptoms  High suspicion of subarachnoid hemorrhage even if CT is normal  Active internal bleeding (eg, gastrointestinal bleeding or urinary bleeding within last 21 days)  Known bleeding diathesis, including but not limited to — Platelet count <100 000 mm3 — Patients who received heparin in last 48 hours; have elevated PTT — Recent anticoagulant use (eg, coumadin); have elevated PT

  39. Fibrinolytic Therapy: Yes/No Checklist Exclusion Criteria (cont’d) (all “No” boxes must be checked before fibrinolytics are given): No  <3 mo ago: intracranial surgery, head trauma, previous stroke  <14 days ago: major surgery or serious trauma  <7 days ago: lumbar puncture  Recent arterial puncture at noncompressible site  History of intracranial hemorrhage, AV malformation, or aneurysm  Witnessed seizure at start of stroke  Recent acute myocardial infarction  SBP >185 mm Hg/DBP >110 mm Hg; confirmed several times  BP must be treated aggressively to bring within these limits

  40. Montana Stroke Initiative http://montanastroke.org

More Related